mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
Combination therapeutic strategies for aRCC patients with bone metastases
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Part 1: Why test?
Part 2: How to get biopsies for testing?
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Part 4: Clinical decision making - Interpretation of next generation sequencing results
Screen-detectable cancers account for majority of early-onset cancer cases under age 50
AACR 2026: Latest video and news updates here
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour